Compare VTRS & RGLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTRS | RGLD |
|---|---|---|
| Founded | 1961 | 1981 |
| Country | United States | United States |
| Employees | 30000 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Precious Metals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7B | 22.2B |
| IPO Year | 2019 | 1995 |
| Metric | VTRS | RGLD |
|---|---|---|
| Price | $16.72 | $248.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $13.50 | ★ $262.17 |
| AVG Volume (30 Days) | ★ 6.7M | 602.4K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.21% | 0.82% |
| EPS Growth | N/A | ★ 32.74 |
| EPS | 0.05 | ★ 6.07 |
| Revenue | ★ $14,299,900,000.00 | $1,030,471,000.00 |
| Revenue This Year | $4.41 | $89.85 |
| Revenue Next Year | $1.96 | $5.05 |
| P/E Ratio | $333.00 | ★ $41.38 |
| Revenue Growth | N/A | ★ 43.24 |
| 52 Week Low | $9.43 | $168.88 |
| 52 Week High | $18.39 | $306.25 |
| Indicator | VTRS | RGLD |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 53.30 |
| Support Level | $15.89 | $214.71 |
| Resistance Level | $17.22 | $274.21 |
| Average True Range (ATR) | 0.41 | 6.78 |
| MACD | 0.00 | -3.23 |
| Stochastic Oscillator | 45.69 | 26.16 |
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.